Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
Wyeth’s Winning Ways: Big Pharma Bounces Back

20 Apr 07

After a year or so of relatively disappointing results from Big Pharma, there seems to be a new wave of optimism sweeping across the industry.
Paul Hartigan

eyeforPharma announces dates for New Concept in Interactive Webinar Events to reach more pharma executives online

11 Apr 07

The Sales Technology & CRM Webinar will take place at 15.00 GMT/10.00 EST, 24th May 2007
Richard Bracchi

A Gala Tribute to Global Copycats

03 Apr 07

Over the decade, the art of copying and stealing other people's content and ideas has settled comfortably in the mainstream across the globe. What formerly would constitute an act of piracy is now a commonplace, everyday occurrence. Isn't it time to give these 'borrowers' a tribute, host a gala dinner and hand out awards?
Naseem Javed

Improving, developing and integrating your e-Clinical Systems...

20 Mar 07

Covering all the major topics surrounding EDC and other e-Clinical technologies, this year’s e-Clinical Trials event will also look carefully at how to integrate a range of systems for a successful e-Clinical programme and bring you up-to-date on current standards and the latest technological options. Delegates will also benefit from a highly detailed interactive workshop on managing e-Clinical Trials in exotic and difficult locations. Furthermore, This year’s e-Clinical Trials conference wil
Amir Sebahat

Weight management is not enough for cannabinoid type 1 (CB1) receptor antagonists to become a commercial success

08 Mar 07

Huge clinical development program of first-in-class CB1 antagonist rimonabant to show benefits beyond weight reduction and avoid image as life-style drug
La Merie Business Intelligence

The new class of dipeptidyl peptidase IV (DPP-IV) inhibitors has one clear leader and many followers

01 Mar 07

Merck & Co clearly leads the field of DPP-IV inhibitors which has many followers in clinical development. The first companies already abandoned the field.
La Merie Business Intelligence

TOP Classes of Biologics with 2006 Sales of US$ 63.8 bln

26 Feb 07

Sales of the major cancer antibodies grew by 57 % to US$ 10.6 bln in 2006. Cancer antibodies are challenging the still no. 1 selling class of erythropoietins with 2006 sales of US$ 11.9 bln, but the lowest growth rate (6.4 %), and got ahead of TNF antibodies which posted sales of 10.3 bln (+ 25 %).
La Merie Business Intelligence

The market of recombinant coagulation factors is growing with next generation products

14 Feb 07

The growing market of recombinant coagulation factors posted 2006 sales of more than US$ 4.6 bln. The four market leaders compete with a staggered series of next generation products and face competition by new entrants into the various segments of the field
La Merie Business Intelligence

Dosing convenience is mandatory to keep pace in the pipeline race of GLP-1 analogs for type 2 diabetes

05 Feb 07

The emerging market of GLP-1 analogs with 2006 sales of US$ 430.2 mln in the first full market year of twice-daily exenatide attracts other players in the diabetes field, but urges them to top exenatide by more convenient products
La Merie Business Intelligence

Overview On 2006 Sales Of TOP 20 Biologics To Be Released On February 26

02 Feb 07

A free compilation of the 2006 sales of the TOP 20 blockbuster and other major recombinant antibodies and proteins will be provided by La Merie Business Intelligence starting February 26
La Merie Business Intelligence

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.